Rare EGFR Variant Tied to 25-Fold Lung Cancer Risk in Never-Smokers
Two reports describe a rare inherited EGFR mutation that may help explain why some people who never smoked develop lung cancer.
Two new reports highlight a rare inherited EGFR mutation as a possible explanation for lung cancer in people who have never smoked. Both Fierce Biotech and STAT describe the variant as very rare and associated with a roughly 25-fold increase in lung cancer risk.
The reports agree that the effect is large compared with smoking: Fierce Biotech notes that smoking alone increased risk by about 4 times in the same context. Because the variant is germline, it is inherited rather than acquired, which could make it a useful marker for identifying high-risk never-smokers.
There is a small discrepancy in how the risk is framed. Fierce Biotech's headline says the mutation increases lung cancer risk 62 times in never-smokers, while the body of that report and STAT both cite a 25-fold increase. The excerpts do not explain the relationship between those figures, so the 62-fold number should be treated as a headline claim rather than a separate finding.
Sources · 2
More in Medicine & Biotech
Ebola Vaccine Trial Launches in DR Congo Outbreak Zone
Health workers in DR Congo have begun testing whether a vaccine designed for a different Ebola strain can protect against the current outbreak.
Beacon Gene Therapy for Rare Vision Loss Succeeds in Pivotal Trial
A pivotal trial of Beacon Therapeutics' gene therapy for X-linked retinitis pigmentosa improved visual acuity, clearing the path toward an FDA submission.
Alkermes orexin agonist shows early promise for ADHD
Early-stage data suggest Alkermes' orexin agonist could expand the drug class beyond sleep disorders into ADHD.
Telix to Buy ITM for $1.65B, Challenging Novartis in Radiopharma
The acquisition gives Telix a late-stage pipeline and supply network that could compete with Novartis' Lutathera.